Interstitial pneumonitis associated with infliximab therapy.

Abstract	Interstitial pneumonitis is a well documented, rare complication of methotrexate (MTX). We describe a patient with rheumatoid arthritis (RA) taking MTX for more than 3 years who then developed severe interstitial pneumonitis after a third infliximab infusion. Other similar cases are reviewed. Infliximab may potentiate pulmonary toxicity of MTX.
Authors	Edith Villeneuve, Anne St-Pierre, Boulos Haraoui
Journal	The Journal of rheumatology (J Rheumatol) Vol. 33 Issue 6 Pg. 1189-93 (Jun 2006) ISSN: 0315-162X [Print] Canada
PMID	16622902 (Publication Type: Case Reports, Journal Article)
Chemical References	Antibodies, Monoclonal Antirheumatic Agents Immunosuppressive Agents Prednisolone Infliximab Methotrexate
Topics	Aged Antibodies, Monoclonal (adverse effects) Antirheumatic Agents (adverse effects) Arthritis, Rheumatoid (drug therapy) Drug Therapy, Combination Humans Immunocompromised Host Immunosuppressive Agents (adverse effects) Infliximab Lung Diseases, Interstitial (chemically induced, pathology) Male Methotrexate (adverse effects) Prednisolone (therapeutic use) Radiography, Thoracic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!